Company |
Company |
Value (M) |
Type/product area |
Terms/details |
Date |
APRIL | |||||
Ascendis Pharma A/S (Hellerup, Denmark) |
Sanofi SA (Paris) |
ND |
Sanofi decided to terminate development of Transcon Insulin for reasons unrelated to the assessment of the Transcon technology |
Sanofi intends to continue development of the Transcon peptide under its ongoing diabetes collaboration with Ascendis |
4/20/15 |
Oncogenex Technologies Inc. (subsidiary of Oncogenex Pharmaceuticals Inc.; Bothell, Wash.) |
Teva Pharmaceuticals Ltd. (Jerusalem) |
$23.2 |
Terminated agreement allowing Oncogenex to regain rights to custirsen, which is in phase III for prostate and lung cancers |
The agreement includes a $23.2M payment from Teva, and Oncogenex will take over all expenses, including those related to the ENSPIRIT trial |
4/28/15 |
Pain Therapeutics Inc. (Austin, Texas) |
Pfizer Inc. (New York) |
ND |
Under terms of a letter agreement with Pfizer, Pain Therapeutics is taking back responsibility for Remoxy |
The two companies agreed to implement a detailed transition plan involving an orderly transfer of a large amount of data, materials, capital equipment and other assets related to Remoxy |
4/22/15 |
|
Notes The date indicated refers to the BioWorld Today issue in which the news item can be found. For more information about individual companies and/or products, see Thomson Reuters Cortellis. | |||||